Table 2.
Some of the important autoantibodies reported in inflammatory myopathies
| Autoantibodies | Disease | Association | References |
|---|---|---|---|
| Anti-tRNA synthetases1 (Anti-Jo; against histidyl tRNA synthetase) |
More common in PM than DM |
Interstitial lung disease |
[63-65] |
| Anti-chromodomain helicase DNA binding proteins (anti-Mi2) |
DM |
Cutaneous lesions |
[3,66,67] |
| Anti-MDA5/Anti-CADM-140 |
DM |
Mucocutaneous lesions; severe lung disease minimal muscle involvement |
[68-70] |
| Anti-TIF1γ2 |
DM |
Malignancy |
[71-73] |
| Anti-nuclear matrix protein (NXP)-2/anti-MJ |
Mostly juvenile DM |
Joint contractures; calcinosis |
[74] |
| Anti-SAE3 |
DM |
Skin and muscle manifestations |
[75] |
| Anti-signal recognition particle |
NM, PM |
Degenerating and regenerating muscle fibers and possible cardiac involvement |
[76-79] |
| Anti-HMG-CoA reductase4 | Statin associated myopathy | Treatment with cholesterol lowering drugs | [80,81] |
PM Polymyositis, DM Dermatomyositis, NM Necrotizing myopathy.
1Additional antisynthetase antibodies found in myositis are targeted against threonyl-tRNA synthetase (PL-7); alanyl-tRNA synthetase (PL-12); isoleucyl-tRNA synthetase (OJ); glycyl-tRNA synthetase (EJ); asparaginyl-tRNA synthetase (KS).
2TIF1γ: Transcription intermediary factor 1γ.
3SAE: Small ubiquitin like modifier activating enzyme.
4HMG-CoA reductase: 3-hydroxy-3-methylglutaryl-coenzymeA reductase.